Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.

Clinical trial NCT07279935 · RECRUITING

Trial details

NCT number: NCT07279935
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2026-05-26
Primary completion: 2030-05-18
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.